Bactericidal and Inhibitory Activity of Enrofloxacin and Other Fluoroquinolones in Small Animal Pathogens

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 21, Issue SUPPL. 12, 1999, Pages 19-25

  Pirro, F ^a   Edingloh, M ^a   Schmeer, N ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347786367     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hannan PCT, Windsor GD, de Jong A, et al: Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrob Agents Chemother 41:2037-2040, 1997.
2. Pirro F, Scheer M, de Jong A: Additive in vitro activity of enrofloxacin and its main metabolite ciprofloxacin. Pisa, Italy, Proc 14th Annual Congress of the ESVD-ECVD, 1997, p 199.
3. Schacht P: Clinical use of quinolones, in Kuhlmann J, Dalhoff A, Zeiler HJ (eds): Quinolone Antibacterials. Berlin, Springer, 421-453, 1998.
4. Scheer M: Studies on the antibacterial activity of Baytril. Vet Med Rev 2/87, 90-99, 1987.
5. Brown SA: Fluoroquinolones in animal health. J Vet Pharmacol Ther 19:1-14, 1996.
6. Gruet P, Richard P, Thomas E, Autefage A: Prevention of surgical infections in dogs with a single intravenous injection of marbofloxacin: An experimental model. Vet Rec 140:199-202, 1997.
7. van den Hoven R: A multi-centre observational study on the efficacy of Dicural Palatabs (difloxacin) for the treatment of canine cystitis. J Vet Pharmacol Ther 20 (Suppl 1):181-218, 1997.
8. Cohen MA, Huband MD, Yoder SL, et al: Bacterial eradication by clinafloxacin, Cl-900, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies. J Antimicrob Chemother 41:605-614, 1998.
9. MacGowan AP, Wootton M, Hedges AJ, et al: A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using representative β-lactam, aminoglycoside and fluoroquinolone. J Antimicrob Chemother 38:193-203, 1996.
10. Hawkins EC, Boothe DM, Guinn A, et al: Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. J Vet Pharmacol Ther 21:18-23, 1998.
11. Heinen E: Comparative pharmacokinetics of enrofloxacin and difloxacin as well as their main metabolites in dogs. Proceedings of the Third International Veterinary Symposium on Fluoroquinolones. Suppl Compend Contin Educ Pract Vet 21(12):12-18.
12. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals. Proposed Standard. NCCLS document M31-A. Villanova, PA, National Committee for Clinical Laboratory Standards, 1998.
13. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard. M7-A4, Vol. 17, No.2. Villanova, PA, National Committee for Clinical Laboratory Standards, 1997.
14. Deutsches Institut für Normung e.V.: Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika, DIN 58940, DIN-Taschenbuch 222, 1992.
15. Stegemann M, Ciszewski DD, Copeland DD: Antimicrobial susceptibility patterns of bacterial isolates from dogs and cats in the United States and comparison of enrofloxacin MICs by microbroth dilution and E-test methods. (Submitted for publication.)
16. Stegemann M, Heukamp U, Scheer M, Krebber R: Kinetics of antibacterial activity after administration of enrofloxacin in dog serum and skin: In vitro susceptibility of field isolates. Proceedings of the Second International Veterinary Symposium on Fluoroquinolones. Suppl Compend Contin Educ Pract Vet 18(2)30-34, 1996.
17. Holm B, Raue H, Bergström K, et al: Antibiotic susceptibility of staphylococci isolated in Sweden: Primary and recurring canine pyoderma. Pisa, Italy, Proc 14th Annual Congress of the ESVD-ECVD, 1997, p 192.
18. Pellerin JL, Bourdeau P, Sebbag H, Person JM: Epidemiosurveillance of antimicrobial compound resistance of Staphylococcus intermedius clinical isolates from canine pyodermas. Comp Immunol Microbiol Infect Dis 21(2): 115-133, 1998.
19. Watts JL, Salmon SA, Sanchez MS, Yancey RJ: In vitro activity of premafloxacin, a new extended spectrum fluoroquinolone, against pathogens of veterinary importance. Antimicrob Agents Chemother 41:1190-1192, 1997.
20. Speakman AJ, Binns SH, Dawson S, et al: Antimicrobial susceptibility of Bordetella bronchiseptica isolates from cats and a comparison of the agar dilution and E-test methods. Vet Microbiol 54:63-72, 1997.
21. Wetzstein HG, de Jong A: In vitro bactericidal activity and postantibiotic effect of fluoroquinolones used in veterinary medicine. Proceedings of the Second International Veterinary Symposium on Fluoroquinolones. Suppl Compend Contin Educ Pract Vet 18(2):22-29, 1996.